Click Therapeutics Launches Additional Randomized Clinical Study In Migraine, Conducted In Partnership With Syneos Health
Portfolio Pulse from Happy Mohamed
Click Therapeutics has launched its second active randomized clinical trial in partnership with Syneos Health (NASDAQ:SYNH) to test digital interventions in migraine patients. The trial will evaluate the efficacy and safety of digital therapeutics for the prevention of episodic migraine in patients receiving CGRP inhibitor therapy. The trial will be fully remote and decentralized, allowing patients to participate from anywhere using their own devices.
August 04, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syneos Health is partnering with Click Therapeutics for a second clinical trial testing digital interventions in migraine patients. The partnership could potentially enhance Syneos Health's reputation in the biopharmaceutical solutions sector.
The partnership with Click Therapeutics for a second clinical trial could potentially enhance Syneos Health's reputation and visibility in the biopharmaceutical solutions sector. This could lead to increased investor confidence and potentially a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80